Radiopharm Theranostics furnishes ASX notice on 6-K

Radiopharm Theranostics Limited furnished a Form 6-K to provide U.S. investors with a copy of an announcement previously released on the Australian Securities Exchange.

Accepted by SEC EDGAR 10/07/2025 - 06:26 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Radiopharm Theranostics Limited furnished a Form 6-K to provide U.S. investors with a copy of an announcement previously released on the Australian Securities Exchange. The attached Exhibit 99.1 is a notification regarding the company’s unquoted securities. The filing is expressly treated as furnished, not filed, under U.S. securities laws.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Radiopharm Theranostics (RADX) report in this Form 6-K?

Radiopharm Theranostics uses this Form 6-K to furnish a copy of an announcement made on the Australian Securities Exchange. The filing mainly serves to share that information with U.S. investors and includes one exhibit relating to unquoted securities.

What is Exhibit 99.1 in Radiopharm Theranostics (RADX) October 2025 Form 6-K?

Exhibit 99.1 is titled “Notification regarding unquoted securities - RAD.” It represents the company’s Australian Securities Exchange announcement and provides details about certain unquoted securities, made available to U.S. investors through this furnished Form 6-K.

Is the Radiopharm Theranostics (RADX) October 7, 2025 Form 6-K considered filed with the SEC?

No, the company states this Form 6-K, including its exhibit, is furnished rather than filed for purposes of the U.S. Exchange Act. It also will not be incorporated into other securities filings unless specifically referenced by the company.

Who signed the October 2025 Form 6-K for Radiopharm Theranostics (RADX)?

The Form 6-K was signed on behalf of Radiopharm Theranostics Limited by Company Secretary Phillip Hains. The signature confirms the company’s authorization of the furnished ASX announcement relating to unquoted securities on October 7, 2025.

Why did Radiopharm Theranostics (RADX) reference the Australian Securities Exchange in this Form 6-K?

Radiopharm Theranostics referenced the Australian Securities Exchange because the underlying announcement was originally published there. The Form 6-K makes that ASX notification regarding unquoted securities accessible to U.S. investors through the SEC’s disclosure system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on October 7, 2025 titled:

- “Notification regarding unquoted securities - RAD”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Notification regarding unquoted securities - RAD

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 7, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3